Physician profile
Jacqueline E Todd
NPI 1487815130
$3,249.48
in general payments reported to CMS, 2019-2025
26 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $194 · 2021: $93.12 · 2022: $775 · 2023: $607 · 2024: $150 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $492.60 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $381.00 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $318.42 | 2022-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $288.37 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $282.49 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $255.54 | 2021-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $184.45 | 2019-2025 | |
| Eisai INC. | $129.57 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $98.75 | 2022 | |
| Idorsia Pharmaceuticals US INC | $97.69 | 2022-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $83.94 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $78.27 | 2025 | Rezdiffra |
| Abbott Laboratories | $77.68 | 2022-2025 | Freestyle Libre 2 |
| Astellas Pharma US INC | $63.84 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $62.80 | 2023-2025 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $55.29 | 2022-2023 | Steglatro, Steglujan, Januvia |
| Amarin Pharma, INC. | $54.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $46.16 | 2019-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $37.61 | 2022 | |
| Almatica Pharma LLC | $33.26 | 2021-2022 | |
| Dexcom, INC. | $30.56 | 2023-2025 | Dexcom G6 Transmitter |
| Insmed, INC. | $24.58 | 2025 | Brinsupri, Arikayce |
| Braintree Laboratories, INC. | $22.32 | 2024 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $17.98 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $16.82 | 2025 | Zoryve |
| Allergan, INC. | $14.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.